TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy - Takeaways - MDSpire

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • By

  • Carolina Kessler

  • Melanie von Brandenstein

  • Niklas Klümper

  • Philipp Krausewitz

  • Enno Storz

  • Constantin Rieger

  • Laurenz Sperber

  • Pia Paffenholz

  • Yuri Tolkach

  • Ralph Wirtz

  • Markus Eckstein

  • Axel Heidenreich

  • Richard Weiten

  • September 1, 2025

  • 0 min

Share

  • 1

    Papillary renal cell carcinoma (pRCC) accounts for approximately 15% of all renal cell carcinoma cases, highlighting its prevalence among non-clear RCC subtypes.

  • 2

    The ARON-1 study showed that immune-oncology combinations significantly improved progression-free survival in metastatic pRCC compared to tyrosine kinase inhibitors.

  • 3

    Antibody-drug conjugates (ADCs) like sacituzumab govitecan target TROP-2, which is overexpressed in various epithelial tumors, including pRCC.

  • 4

    TROP-2 expression was evaluated in a cohort of RCC patients, revealing its potential as a therapeutic target for antibody-drug conjugate therapy.

  • 5

    The study underscores the need for new therapeutic strategies in pRCC due to the historically poor prognosis and limited treatment options.

Original Source(s)

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • by Carolina Kessler, Melanie von Brandenstein, Niklas Klümper, Philipp Krausewitz, Enno Storz, Constantin Rieger, Laurenz Sperber, Pia Paffenholz, Yuri Tolkach, Ralph Wirtz, Markus Eckstein, Axel Heidenreich, Richard Weiten

  • September 1, 2025

Related Content

Roswell Park Set to Open Several New Trials this Year for Innovative CAR T-Cell Therapies

CAR T-cell therapies are the future of cancer treatment and Roswell Park Comprehensive Cancer Center is preparing to open a number of new trials based on research originating here and in partnership with the industry.

  • March 17, 2025

  • 2 min
Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020

Kidney Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.

  • March 3, 2025

  • 1 min